Market Place
Sourcing Support
MEI and Kyowa Kirin to discontinue development of zandelisib outside Japan
07 Dec 2022 //
PHARMACEUTICAL-TECHNOLOGY
MEI Pharma & Kyowa Kirin Announce Discontinuation of Zandelisib Outside of Japan
06 Dec 2022 //
BUSINESSWIRE
MEI Pharma Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
01 Aug 2022 //
BUSINESSWIRE
MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology
18 Jul 2022 //
BUSINESSWIRE
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at ASCO 2022
04 Jun 2022 //
BUSINESSWIRE
FDA rebuffs MEI, Kyowa Kirin as another cancer drug class draws scrutiny
26 Mar 2022 //
BIOPHARMADIVE
MEI Pharma, Kyowa Kirin Provide Regulatory Update on Zandelisib
24 Mar 2022 //
BUSINESSWIRE
Mei, with Bayer and Gilead in its sights, posts pivotal data
30 Nov 2021 //
FIERCEBIOTECH
MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL
29 Nov 2021 //
BUSINESSWIRE
MEI Pharma and Kyowa Kirin receive Orphan Drug Designation for Zandelisib
10 Nov 2021 //
BUSINESSWIRE
MEI and Kyowa Kirin Announce First Patient Dosed in the Phase 3 COASTAL Study
17 Aug 2021 //
PRNEWSWIRE
MEI Pharma & Kyowa Kirin Announce 1st Patient with Marginal Zone Lymphoma Dosed
07 Jun 2021 //
PRNEWSWIRE
MEI Pharma Announces Expansion of Phase 1b Study Evaluating Zandelisib
04 Jan 2021 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.